3-Hidroksipiridin-4-oni (II. dio): Biološka primjena kao kelatora željeza. (Croatian)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Alternate Title:
      3-Hydroxypyridin-4-ones (Part II): Biological Application as Iron Chelating Agents. (English)
    • Abstract:
      Selectivity towards trivalent metal cations, especially Fe(III), is the primary basis of a number of 3-hydroxypyridin-4-ones' biological activities. These compounds have high potential in the treatment of iron overload diseases, in various blood pathologies such as thalassemia and hemochromatosis, as well as in the treatment of neurodegenerative diseases, such as Alzheimer's disease. Beside deferiprone, the only 3-hydroxypyridin-4-one based iron(III) chelating agent which has been used clinically for more than 30 years, this review will also present other most significant and potentially biologically active chelators with 3-hydroxypyridin-4-one core. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Selektivnost prema keliranju trovalentnih kationa metala, u prvom redu Fe(III), osnova je brojnih bioloških učinaka derivata 3-hidroksipiridin-4-ona. Ti spojevi najviše potencijala pokazuju u liječenju oboljenja uslijed kojih dolazi do nakupljanja željeza u organizmu, kao što su razna krvna oboljenja poput talasemije i hemokromatoze te u liječenju neurodegenerativnih bolesti, primjerice Alzheimerove bolesti. Osim deferiprona, koji je već više od 30 godina u kliničkoj upotrebi kao kelator Fe(III), u ovom radu dan je pregled i ostalih najznačajnijih kelatora 3-hidroksipiridin-4-onske strukture s potencijalnom biološkom primjenom. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Kemija u Industriji is the property of Croatian Society of Chemical Engineers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)